Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

K. N. Moore, A. M. Oza, N. Colombo, A. Oaknin, G. Scambia, D. Lorusso, G. E. Konecny, S. Banerjee, C. G. Murphy, J. L. Tanyi, H. Hirte, J. A. Konner, P. C. Lim, M. Prasad-Hayes, B. J. Monk, P. Pautier, J. Wang, A. Berkenblit, I. Vergote, M. J. Birrer

Research output: Contribution to journalArticlepeer-review

96 Scopus citations

Fingerprint

Dive into the research topics of 'Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I'. Together they form a unique fingerprint.

Medicine & Life Sciences